TNF and immunodeficiency disease: Ilham et al. [20] also conducted a large retrospective cohort study on over thirteen thousand patients, including recipients of solid organ transplants or hematopoietic stem cell transplants, patients diagnosed with primary or secondary immunodeficiency disorders, and those receiving anti-TNF agents (the latter constituting 24% of the sample).